James S. Shannon Transitions to Chairman of the Board of Directors for MannKind
December 10 2020 - 8:00AM
MannKind
Corporation
(Nasdaq:
MNKD) today announced that James S. Shannon, M.D.,
MRCP (UK) has been named the new Chairman of the Board of Directors
effective December 9, 2020. Kent Kresa, the former Chairman of the
Board, will continue to serve on MannKind’s Board of Directors and
as Chair of the Compensation Committee of the Board.
“Kent has done an incredible job leading the
Board – as Chairman for the last four years and as Lead Independent
Director for an additional five years prior to that,” said James
Shannon. “As Al Mann’s successor, Kent helped continue Al’s mission
of addressing the unmet needs of patients with diabetes and other
serious illnesses. Since joining the Board in 2004, Kent has
contributed significantly to the Company's progress and he will
certainly continue to do so. We are grateful for his leadership and
we look forward to continuing to benefit from his experience.”
Dr. Shannon served on the Board from February
2010 until April 2012 then rejoined the Board in May 2015. Dr.
Shannon is a recognized pharmaceutical industry leader with more
than 20 years of experience in senior leadership positions. He
served as the Chief Medical Officer for GlaxoSmithKline from 2012
-2015 and prior to this, served as Global Head of Pharma
Development for Novartis AG based in Basel, Switzerland. Dr.
Shannon is trained in Medicine and Cardiology and received his
undergraduate and postgraduate degrees at Queen's University of
Belfast and is a Member of the Royal College of Physicians (UK). He
currently serves on the boards of several companies including
Horizon Therapeutics, Kyowa Kirin, Immodulon Therapeutics Limited,
ProQR Therapeutics NV, and myTomorrows.
"I would like to thank Kent for our partnership
during my time with MannKind,” said Michael Castagna, Chief
Executive Officer of MannKind. “He has been a great mentor, for
which I will be forever thankful. Having James as Kent’s successor
speaks to the caliber of our Board. James’ keen insight and
leadership experience in the pharmaceutical industry will be
invaluable as we continue to advance the pipeline and focus on
developing innovative medicines for both endocrinology and orphan
lung diseases."
About MannKind
Corporation
MannKind Corporation (Nasdaq: MNKD) focuses
on the development and commercialization of inhaled therapeutic
products for patients with endocrine and orphan lung
diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin
in the United States, where it is available by prescription
from pharmacies nationwide. MannKind is headquartered
in Westlake Village, California, and has a state-of-the art
manufacturing facility in Danbury, Connecticut. The Company
also employs field sales and medical representatives across
the U.S. For further information,
visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Words such as
"believes," "anticipates," "plans," "expects," "intends," "will,"
"goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon MannKind's current
expectations. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties detailed
in MannKind's filings with the SEC. For a discussion
of these and other factors, please refer to MannKind’s annual
report on Form 10-K for the year ended December 31, 2019 as
well as MannKind’s other filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and MannKind undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date of this press
release.
Company
Contact:818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024